IMT is a private Australian biotechnology startup company based in Sydney Australia that focuses on the clinical & commercial development of therapeutic anti-IgD monoclonal antibody (mAb) as a first-in-class disease-modifying mAb drug for human autoimmune diseases, allergic conditions and B-CLL.
Dr Tue (Tommie) Gia Nguyen – B. Biotech, M. BioPharm, PhD.
CEO/CSO & Founder of IMT
Sydney NSW 2000, Australia.
Phone: +61 41041 5135
Email: CEO-IMT@Igdmabtech.com or IgD.Mabtechnology.Group@gmail.com
Website: IMT, LinkedIn, ResearchGate, Google Scholar
IgD Mab Technology (IMT) 